company background image
SLNO

Soleno Therapeutics NasdaqCM:SLNO Stock Report

Last Price

US$0.19

Market Cap

US$23.4m

7D

8.1%

1Y

-77.1%

Updated

15 Aug, 2022

Data

Company Financials +
SLNO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SLNO Stock Overview

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Soleno Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Soleno Therapeutics
Historical stock prices
Current Share PriceUS$0.19
52 Week HighUS$0.97
52 Week LowUS$0.13
Beta0.24
1 Month Change4.28%
3 Month Change1.16%
1 Year Change-77.09%
3 Year Change-89.92%
5 Year Change-89.31%
Change since IPO-99.04%

Recent News & Updates

Aug 12
Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Jul 20

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Soleno Therapeutics (NASDAQ:SLNO) is trading 49% higher premarket after the U.S. Food and Drug Administration said that data from a withdrawal phase study would be sufficient to address concerns regarding the overall efficacy data supportive of a New Drug Application (NDA) submission for its drug DCCR (diazoxide choline) to treat Prader-Willi syndrome. The stock is set to touch its highest in 4 months. Soleno had submitted a proposal to add a withdrawal period to Study C602 in order to obtain additional controlled data requested by the FDA to support an NDA, the company said.  The Company continues to work collaboratively with the FDA to finalize specific details of the study design and plans to initiate the randomized withdrawal period in the current quarter, with top-line data expected in the first quarter of 2023. Prader-Willi syndrome is genetic disorder that causes obesity, intellectual disability and shortness in height.

May 10
Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

SLNOUS BiotechsUS Market
7D8.1%1.4%3.6%
1Y-77.1%-19.6%-9.6%

Return vs Industry: SLNO underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: SLNO underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is SLNO's price volatile compared to industry and market?
SLNO volatility
SLNO Average Weekly Movement12.6%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: SLNO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: SLNO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199920Anish Bhatnagarhttps://soleno.life

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.

Soleno Therapeutics, Inc. Fundamentals Summary

How do Soleno Therapeutics's earnings and revenue compare to its market cap?
SLNO fundamental statistics
Market CapUS$23.39m
Earnings (TTM)-US$23.42m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SLNO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$23.42m
Earnings-US$23.42m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.19
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SLNO perform over the long term?

See historical performance and comparison